<DOC>
	<DOC>NCT00160069</DOC>
	<brief_summary>Phase 2 study to investigate the efficacy and tolerability of epothilone ZK 219477 in patients with stage IIIb or stage IV non-small-cell lung cancer.</brief_summary>
	<brief_title>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Nonsmallcell lung cancer Only one previous chemotherapy with a platinumcontaining drug Use of highly effective birth control methods in females of childbearing potential No more than 1 previous chemotherapy for advanced disease Previous participation in another trial within the last 4 weeks Breast feeding Active infections</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Stage IIIB or stage IV non-small-cell lung cancer.</keyword>
</DOC>